PureTech Health plc
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 7.0
- Dividend yield
- –
About PureTech Health
Pharmaceutical Preparations, SIC 2834
PureTech Health operates as a biotherapeutics entity focused on developing treatments across several dedicated operational segments, primarily targeting oncology and related clinical areas through subsidiary operating units. The company conducts its research and development programs both directly and through subsidiary operating companies such as Gallop Oncology, Entrega, PureTech LYT, and PureTech LYT 100. These programs are designed to advance targeted biotherapeutic candidates for patients, while also managing historical interests in deconsolidated former subsidiaries and inactive corporate entities.
The group maintains its operating activities across distinct organizational units including Wholly-Owned segments, Controlled Founded Entities, and Parent Company and Other operations. PureTech conducts business activities supported by technical facilities featuring specialized laboratory and manufacturing equipment, computer infrastructure, and fixtures. Corporate operations and segment administrative activities are coordinated across these designated operating divisions and corporate holding structures.
Summary of the business section of PureTech Health's latest annual report, written by StockData.
Company profile
Company
- Legal name
- PureTech Health plc
- Headquarters
- Boston, MA
- Address
- 6 Tide Street, Suite 400 02210
- Phone
- (617) 482-2333
- Website
- puretechhealth.com
- Industry
- Pharmaceutical Preparations
- Incorporated in
- X0
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- PTCHF
- Other tickers
- PRTCY
- Exchange
- OTC
- Shares outstanding
- 242M, Dec 31, 2025
- Filer category
- Accelerated filer
- SEC CIK
- 1782999
- CUSIP
- 746237106
- ISIN
- US7462371060
- LEI
- 213800LVPDNO2Z9T9I39
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
No recent ownership filings by officers or directors
PureTech Health's leadership is listed in its proxy statement (Form DEF 14A).
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| May 21, 2026 | Deregistration | Termination of SEC registration (Form 15) |
| May 11, 2026 | Delisting | Notice of delisting from exchange (Form 25) |